Clinicopathological Factors Associated to HER-2 Status in a Hospital-based Sample of Breast Cancer Patients in Puerto Rico

被引:0
作者
Ortiz, Ana P. [1 ,2 ]
Frias, Orquidea [1 ]
Gonzalez-Keelan, Carmen [3 ]
Suarez, Erick [2 ]
Capo, David [2 ]
Perez, Javier [4 ]
Cabanillas, Fernando [4 ,5 ]
Mora, Edna [6 ]
机构
[1] Univ Puerto Rico, Ctr Comprehens Canc, Canc Control & Populat Sci Program, San Juan, PR 00936 USA
[2] Univ Puerto Rico, Grad Sch Publ Hlth, Dept Biostat & Epidemiol, San Juan, PR 00936 USA
[3] Univ Puerto Rico, Sch Med, Dept Pathol, San Juan, PR 00936 USA
[4] Univ Puerto Rico, Ctr Comprehens Canc, Puerto Rico Cent Canc Registry, San Juan, PR 00936 USA
[5] Auxilio Mutuo Hosp, Ctr Canc, San Juan, PR 00919 USA
[6] Univ Puerto Rico, Dept Surg, San Juan, PR 00936 USA
关键词
Breast cancer; HER-2; Puerto Rico; ESTROGEN-RECEPTOR; AFRICAN-AMERICAN; OVER-EXPRESSION; CARCINOMA; C-ERBB-2; WOMEN; AMPLIFICATION; OVEREXPRESSION; PROGRESSION; PROGNOSIS;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Breast cancer is the most common female malignancy in Puerto Rico. Cases with human epidermal growth factor receptor 2 (HER-2) oncoprotein overamplification are associated with aggressive clinical behavior. Given the limited availability of information for Puerto Rico, we aimed to evaluate the prevalence and clinical correlates of HER-2 gene overexpression among a hospital-based female population of breast cancer cases. We analyzed data from 1,049 female patients with invasive breast cancer (diagnosed 2000-2005) at the I. Gonzalez Martinez Oncologic Hospital and the Auxilio Mutuo Hospital. HER-2 status and other clinical characteristics were retrieved from the hospitals' cancer registries, from the Puerto Rico Central Cancer Registry, and from a review of medical and pathological records. Prevalence odds ratios were estimated with 95% confidence intervals, using logistic regression models to quantify the association between HER-2 status and different clinicophatological factors. The overall prevalence of positive HER-2 expression was 22.5%. In the multivariate logistic regression model, factors significantly associated with HER-2 positivity included a diagnosis age of <50 years, having a tumor with negative progesterone receptor (PR) status, and having regional disease (p < 0.05). No significant differences in HER-2 positivity were observed by tumor histology or estrogen receptor (ER) status (p > 0.05). This is the most comprehensive epidemiological study to date on HER-2 status in Puerto Rico. The prevalence and correlates of HER-2 overexpression in this study are comparable to those observed in US populations. Study results will aid in the development of breast cancer control strategies in Puerto Rico. [P R Health Sci J 2010;3:265-271]
引用
收藏
页码:265 / 271
页数:7
相关论文
共 46 条
  • [1] Racial differences in genetic factors associated with breast cancer
    Ademuyiwa, FO
    Olopade, OI
    [J]. CANCER AND METASTASIS REVIEWS, 2003, 22 (01) : 47 - 53
  • [2] Ahmad A, 2009, JCPSP-J COLL PHYSICI, V19, P297, DOI 05.2009/JCPSP.297299
  • [3] OVEREXPRESSION OF HER-2 NEU AND ITS RELATIONSHIP WITH OTHER PROGNOSTIC FACTORS CHANGE DURING THE PROGRESSION OF INSITU TO INVASIVE BREAST-CANCER
    ALLRED, DC
    CLARK, GM
    MOLINA, R
    TANDON, AK
    SCHNITT, SJ
    GILCHRIST, KW
    OSBORNE, CK
    TORMEY, DC
    MCGUIRE, WL
    [J]. HUMAN PATHOLOGY, 1992, 23 (09) : 974 - 979
  • [4] [Anonymous], 2004, GLOBOCAN 2002 CANC I
  • [5] [Anonymous], 2013, International Classification of disease for Oncology
  • [6] [Anonymous], 2001, NIH Pub
  • [7] Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) -negative, but with grade in those with ER-Positive early-stage breast cancer suitable for cytotoxic chemotherapy
    Bartlett, John M. S.
    Ellis, Ian O.
    Dowsett, Mitch
    Mallon, Elizabeth A.
    Cameron, David A.
    Johnston, Stephen
    Hall, Emma
    A'Hern, Roger
    Peckitt, Clare
    Bliss, Judith M.
    Johnson, Lindsay
    Barrett-Lee, Peter
    Ellis, Paul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4423 - 4430
  • [8] 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
    Bast, RC
    Ravdin, P
    Hayes, DF
    Bates, S
    Fritsche, H
    Jessup, JM
    Kemeny, N
    Locker, GY
    Mennel, RG
    Somerfield, MR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1865 - 1878
  • [9] The association of HER-2/neu amplification with breast cancer recurrence
    Carr, JA
    Havstad, S
    Zarbo, RJ
    Divine, G
    Mackowiak, P
    Velanovich, V
    [J]. ARCHIVES OF SURGERY, 2000, 135 (12) : 1469 - 1474
  • [10] CLARK GM, 1991, CANCER RES, V51, P944